Inhibition of angiogenesis using glycolysis inhibitors Universiteit Antwerpen
Aberrant angiogenesis contributes to many pathophysiological conditions such as cancer and diabetes mellitus. Current anti-angiogenic therapies aim at targeting key angiogenic growth factors or their endothelial cell-expressed receptors including VEGF and VEGFRs. This strategy, however, often fails to render sustained responses with minimal increased survival rate in treatment of several cancers due to toxicity and drug resistance. A novel ...